Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects

Area of Science:

• Pharmacology
• Transplantation Medicine
• Hepatology

Background:

• Tacrolimus (FK506) is crucial for preventing organ rejection post-transplantation.
• Hepatic drug metabolism, primarily via CYP3A4, can be compromised in liver dysfunction.
• Understanding tacrolimus pharmacokinetics in mild hepatic impairment is essential for safe dosing.

Purpose of the Study:

• To characterize the oral and intravenous pharmacokinetics of tacrolimus in patients with mild hepatic dysfunction.
• To compare these pharmacokinetic parameters with those of healthy subjects.

Main Methods:

• A pharmacokinetic study involving 6 patients with mild hepatic dysfunction.
• Administration of intravenous (0.020 mg/kg) and oral (approx. 0.12 mg/kg) tacrolimus doses.
• Comparison with historical data from normal subjects receiving similar doses.

Main Results:

• Clearance (0.035 L/h/kg) and absolute bioavailability (22.3%) in mild hepatic dysfunction were not substantially different from normal subjects (0.040 L/h/kg, 17.8%).
• Terminal half-life was prolonged in patients with hepatic dysfunction (60.6 hours vs. 34.2 hours).
• Oral bioavailability and time to peak concentration showed minor variations.

Conclusions:

• Patients with mild hepatic impairment can likely be initiated on standard tacrolimus doses.
• Therapeutic drug monitoring is recommended for dose adjustments based on individual response and toxicity.
• These findings support the use of conventional dosing strategies in mild hepatic dysfunction, guided by clinical outcomes.